Tapewire

Nasdaq · USD

SCNI

Scinai Immunotherapeutics Ltd.

Export transactions ↓
Tapewire entity
8547
SEC CIK
0001611747
Parsed reports
26

Last 12 months

Inside the activity.

0 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
June 16, 2026 Filed Jun 18, 2026 18:51 UTC
GERMAIN MARKDirector
GrantOrdinary Shares 120,000,000 $0.00 $0.00
Disclosure

SEC source: 0001178913-26-003261 · zk2635578.xml · nonDerivative · entry 1

GERMAIN MARK · CIK 0001195498 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000,000

F1 · security: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

F2 · shares: Includes 120,000,000 Ordinary Shares represented by restricted share units granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

Read SEC document
June 16, 2026 Filed Jun 18, 2026 18:48 UTC
Reichman AmirDirector · Chief Executive Officer
GrantOrdinary Shares 400,000,000 $0.00 $0.00
Disclosure

SEC source: 0001178913-26-003259 · zk2635577.xml · nonDerivative · entry 1

Reichman Amir · CIK 0001960199 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 711,637,600

F1 · security: The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.

F2 · shares: Includes 400,000,000 Ordinary Shares represented by restricted share units ("RSUs") granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

F3 · balance_after: Includes 71,637,600 Ordinary Shares represented by RSUs granted on January 25, 2024, of which 25% vested on the six-month anniversary thereof, 8.33% vested on the one-year anniversary thereof, and 66.66% vest in two equal annual installments thereafter, subject to the Reporting Person's continued service through such dates. Each RSU represents a contingent right to receive one Ordinary Share upon vesting.

F4 · balance_after: Includes 240,000,000 Ordinary Shares represented by RSUs granted on December 22, 2025, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.